Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma - Quiz - MDSpire

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • By

  • Frida Bugge Askeland

  • Vilhelm Hauge Bugge

  • Anne-Marie Rasmussen

  • Anna Lysén

  • Einar Haukås

  • Magnus Moksnes

  • Anette L. Eilertsen

  • Galina Tsykunova

  • Birgitte Dahl Eiken

  • Nils Morten Leknes

  • Jürgen Rolke

  • Vidar Stavseth

  • Eivind Samstad

  • Randi Fykse Hallstensen

  • Damian Szatkowski

  • Ariane Aasbø Hansen

  • Anita Smith Nilsen

  • Tobias S. Slørdahl

  • Pegah Abdollahi

  • Fredrik Schjesvold

  • December 22, 2025

  • 0 min

Share

Original Source(s)

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • by Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, Anna Lysén, Einar Haukås, Magnus Moksnes, Anette L. Eilertsen, Galina Tsykunova, Birgitte Dahl Eiken, Nils Morten Leknes, Jürgen Rolke, Vidar Stavseth, Eivind Samstad, Randi Fykse Hallstensen, Damian Szatkowski, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Pegah Abdollahi, Fredrik Schjesvold

  • December 22, 2025

Related Content

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min